RxDoctor Payments Data

Robert Murgia, DO

Dermatology · Dover, NHNPI 1063804441

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 33.6% of the total. Reporting peaked in 2024 at $1,548 and has fallen 67.7% since, to $499 in 2025.

$5,883in general payments, 2019–2025

Across 172 payments — averaging $34.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Lilly USA, LLC$674
  • Arcutis Biotherapeutics, Inc.$514
  • Galderma Laboratories, L.p.$262
  • E.r. Squibb & Sons, L.L.C.$238
  • plus $1K from 16 others

What the payments were for

  • Travel & lodging$30%
  • Food & beverage$5,77198%
  • Education$1102%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,883 in reported general payments places this provider in the 70th percentile of 75 dermatology providers in New Hampshire.

See all dermatology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$209,817
Medicare patients
693
Services billed
3,117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa14$287,640
Dupixent PenDupilumab48$178,209
Clobetasol Propionate168$13,237
Ketoconazole325$6,313
Tacrolimus43$5,088
Calcipotriene22$3,845
Clindamycin Phosphate49$1,559
Triamcinolone Acetonide93$1,396
Tretinoin26$1,141
Doxycycline Hyclate42$1,067
Fluocinolone Acetonide21$1,004
Metronidazole27$872
Fluconazole94$820
Nystatin34$601
Cimetidine12$541

Paid to pharmacies, not to this prescriber.

Other dermatology in Dover

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →